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Abstract
Objectives: To examine the prescribing habits of NSAIDs among pediatric medical and surgical practitioners, and
to examine concerns and barriers to their use.
Methods: A sample of 1289 pediatricians, pediatric rheumatologists, sports medicine physicians, pediatric surgeons
and pediatric orthopedic surgeons in the United States and Canada were sent an email link to a 22-question web-
based survey.
Results: 338 surveys (28%) were completed, 84 were undeliverable. Of all respondents, 164 (50%) had never
prescribed a selective cyclooxygenase-2 (COX-2) NSAID. The most common reasons for ever prescribing an NSAID
were musculoskeletal pain, soft-tissue injury, fever, arthritis, fracture, and headache. Compared to traditional NSAIDs,
selective COX-2 NSAIDs were believed to be as safe (42%) or safer (24%); have equal (52%) to greater efficacy (20%)
for pain; have equal (59%) to greater efficacy (15%) for inflammation; and have equal (39%) to improved (44%)
tolerability. Pediatric rheumatologists reported significantly more frequent abdominal pain (81% vs. 23%), epistaxis
(13% vs. 2%), easy bruising (64% vs. 8%), headaches (21% vs. 1%) and fatigue (12% vs. 1%) for traditional NSAIDs
than for selective COX-2 NSAIDs. Prescribing habits of NSAIDs have changed since the voluntary withdrawal of
rofecoxib and valdecoxib; 3% of pediatric rheumatologists reported giving fewer traditional NSAID prescriptions,
and while 57% reported giving fewer selective COX-2 NSAIDs, 26% reported that they no longer prescribed these
medications.
Conclusions: Traditional and selective COX-2 NSAIDs were perceived as safe by pediatric specialists. The data were
compared to the published pediatric safety literature.
Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are
commonly prescribed for the symptomatic relief of pain
and fever in children, and their anti-inflammatory effects
are useful for juvenile arthritis and musculoskeletal
(MSK) disorders. Traditional NSAIDs are non-selective
cyclooxygenase (COX) inhibitors that inhibit both COX-
1 and COX-2 enzymes. Inhibition of COX-1 dependent
prostanoids disrupts cytoprotection of the stomach and
platelet aggregation; therefore, blocking the COX-1
enzyme may result in abdominal pain, gastric irritation
and gastrointestinal ulceration[1]. Inhibition of COX-2
dependent prostanoids, however, mediates anti-inflam-
matory, analgesic and antipyretic effects, and selective
COX-2 inhibitors have diminished the gastrointestinal
toxicities associated with NSAIDs[2,3]. Unfortunately,
large randomized clinical trials of selective COX-2 inhi-
bitors in adults detected an increased incidence of
adverse cardiovascular events[3-6]. Further analysis
demonstrated a similar cardiovascular risk with selective
COX-2 inhibitors and traditional NSAIDs,[7] this risk
likely due to permanent blockade of COX-2 dependent
prostaglandins[8].
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gastric ulcers, are infrequent in the pediatric population
[9-11]. However, many children taking NSAIDs do report
abdominal pain, nausea and anorexia[11,12]. In this
population, a gastroprotective agent such as misoprostol,
or a histamine (H2) blocker or proton-pump inhibitor
along with the NSAID may be helpful[12-14], or for
others a selective COX-2 NSAID may be an option.
NSAIDs are often prescribed “off-label” in pediatrics,
although eight NSAIDs (including aspirin) are approved
by the Food and Drug Administration (FDA) with indi-
cations for fever, pain or juvenile arthritis[15]. Two
other NSAIDs have pediatric indications (indomethacin,
for patent ductus arteriosus (PDA), and ketorolac admi-
nistered in a single dose for pain). There are few studies
of selective COX-2 NSAIDs in children, but include the
treatment of acute post-surgical pain[16,17], juvenile
arthritis[18,19], the arthropathy of hemophilia[20-22],
and in the therapeutic regimen for fibrodysplasia ossifi-
cans progressiva[23]. Overexpression of the COX-2
enzyme has been recognized in childhood brain tumors,
and may be a future target for treatment[24].
Despite the ubiquitous use of NSAIDs by physicians
for pediatric patients, little has been published addres-
sing their safety and tolerability. Limited pharmacoki-
netic studies of celecoxib[25], etodolac[26], and
piroxicam[27] in children indicate significant differences
which necessitate altered dosing.
T h ep r i m a r yo b j e c t i v e so ft h i ss t u d yw e r et os u r v e y
pediatric physicians who prescribe NSAIDs (traditional
and selective COX-2) in order to describe the perceived
efficacy, side effect profiles and adverse events attributa-
ble to this class of drugs. A secondary goal was to com-
pare physician experience and perceptions to the
published safety literature.
Materials and methods
Study Participants
An email inviting physicians to complete a web-based
survey about NSAIDs was sent to 1289 physicians in the
United States (US) and Canada. Random samples of
physician emails were generated from membership ros-
ters of the American Academy of Pediatrics (AAP), the
American Pediatric Surgical Association, and the Pedia-
tric Orthopaedic Society of North America. All mem-
bers of the Sports Medicine Section of the AAP, the
Pediatric Section of the American College of Rheuma-
tology (ACR) and physician members of the Childhood
Arthritis and Rheumatology Research Alliance (CARRA)
were included. Individuals who appeared on more than
one list were sent only one email. This method of com-
pilation of names resulted in an intentional overrepre-
sentation of pediatric rheumatologists and pediatric
sports medicine physicians, two groups of physicians the
investigators believed were frequent prescribers of
NSAIDs. Initial email invitations were sent in May 2005
and two reminder emails were sent to non-responders.
All surveys completed within 8 weeks were tabulated.
Follow-up email requests were then sent to all respon-
dents who indicated that they had observed a cardiovas-
cular event in one or more patients. The study was
approved by the Institutional Review Board at the
Columbia University Medical Center.
Survey Content
Questions were developed to elicit demographic infor-
mation, prescribing practices of NSAIDs, physician per-
ceptions of the frequency and occurrence of NSAID
side effects, patient perceptions of NSAIDs, and atti-
tudes and observations prior to, and following the with-
drawal of rofecoxib (September 2004) and valdecoxib
(April 2005). Questions were refined after pilot testing,
and the final survey (available on request) was 22 ques-
tions or fewer, depending on the responses given,
requiring 10 to 15 minutes to complete. Several ques-
tions asked physicians to determine the frequency of a
response as “frequently” (more than once per week),
“occasionally” (more than once per month), “rarely”
(more than once per year) or “never”.T h e s eq u e s t i o n s
addressed the frequency of prescribing specific drugs,
prescribing for specific indications, observed side effects,
and barriers to prescribing. All data were tabulated and
compiled at the Center for Education Research and Eva-
luation, Columbia University; only de-identified data
were provided to the investigators.
Statistical Analysis
Percentages and frequencies were summarized to report
the proportions of physician groups with different
responses. Where appropriate, comparisons among groups
were performed using chi-square, Fisher’s exact test and
Stuart-Maxwell tests of marginal homogeneity for paired
categorical data. Statistical significance was defined as P <
.05, using Stata 9.0 (College Station, TX) for analyses.
Results
Survey Respondents
1289 emails were sent and 84 were returned because of
undeliverable email addresses. Three hundred and thirty-
eight (28%) surveys were completed. Two respondents
(one rheumatologist, one orthopedic surgeon) did not
treat pediatric patients (<18 years), and six physicians
h a v en e v e rp r e s c r i b e da nN S A I Df o rap e d i a t r i cp a t i e n t .
Demographic data were collected from these surveys.
More than half of respondents were female (56%), and
52% were employed at a university teaching institution.
Physician years in practice were evenly distributed (4%
less than one year, 24% in practice 1 - 5 years, 18% in
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in practice 21 - 30 years, and 6% in practice more than
30 years). Response rates varied by specialty; 168/635
(27%) AAP members ("pediatricians”), 100/247 (40%)
pediatric rheumatologists, 12/106 (11%) sports medicine
specialists, 24/145 (17%) pediatric surgeons, and 43/156
(28%) pediatric orthopedic surgeons responded. The
total number of respondents was greater than 338
because several physicians identified themselves as
belonging to more than one group. For analysis, data
from the sports medicine subset were integrated into
the pediatricians subset because only three respondents
reported exclusively practicing sports medicine.
Data from 330 surveys were analyzed (those respon-
dents who had ever prescribed NSAIDs to a patient less
than 18 years old). Of the 330 physicians, 164 (49.6%)
had never prescribed a selective COX-2 NSAID. By spe-
cialty, 72% (119/165) of pediatricians, 52% (22/42) of
orthopedic surgeons, 79% (19/24) of pediatric surgeons,
and 4% (4/99) of rheumatologists had never prescribed a
selective COX-2 NSAID.
Clinical Indications for NSAIDs
Traditional NSAIDs were prescribed for a myriad of rea-
sons. Among all respondents, the most common reasons
for ever prescribing a traditional NSAID were musculos-
keletal (MSK) pain (91%), soft-tissue injury (82%), fever
(80%), arthritis (78%), and headache (72%). For selective
COX-2 NSAIDs, the most common reasons for ever
prescribing were arthritis (78%), MSK pain (61%), soft
tissue injury (37%), and fracture (23%). Indications for
prescribing traditional and selective COX-2 NSAIDs for
pediatricians and pediatric rheumatologists were similar
(data not shown), except that a greater percentage of
pediatric rheumatologists prescribed NSAIDs for juve-
nile arthritis (49% of pediatricians versus 100% of rheu-
matologists). Selective COX-2 NSAIDs were primarily
prescribed after failure (lack of clinical efficacy or unac-
ceptable side effects) of one or more traditional NSAIDs.
Side Effects of NSAIDs
Respondents were asked to quantify the frequency of
several common and rare side effects of NSAIDs.
Because few side effects overall were reported by non-
rheumatologists in all categories these data are not
shown. Table 1 lists side effects reported by pediatric
rheumatologists for traditional and selective COX-2
NSAIDs. Significantly more frequent reports of several
side effects were noted for traditional NSAIDs compared
to selective COX-2 NSAIDs.
Adverse Cardiovascular Effects
To assess cardiovascular side effects of NSAIDs, ques-
tions asked specifically about stroke, myocardial
infarction, angina, congestive heart failure and unex-
plained cardiac death. Eleven physicians reported that
one or more of their patients had had an event, and
these respondents were contacted (with a 100% response
rate) to obtain further details. The cardiovascular events
were attributed to underlying diagnoses of systemic
lupus erythematosus or antiphospholipid syndrome
(stroke), sickle cell anemia (congestive heart failure,
stroke), hypertension (stroke) or congenital heart disease
(stroke, myocardial infarction and congestive heart fail-
ure). No events were attributed by the physician to the
use of either a traditional or selective COX-2 NSAID.
No unexplained cardiac deaths were reported.
Selective COX-2 NSAIDs
To compare traditional NSAIDs to selective COX-2
NSAIDs, questions were directed only to physicians who
had ever prescribed a COX-2 NSAID (166/330); results
are grouped for all respondents in Figure 1. Respondents
rated COX-2 NSAIDs as equivalent or superior to tradi-
tional NSAIDs for safety (66%), pain relief (72%), relief
of inflammation (74%) and tolerability (83%).
Attitude changes of patients and/or their caregivers (as
expressed to their physician) prior to, and following, the
voluntary withdrawal of rofecoxib and valdecoxib were
explored. Figure 2 illustrates that specific patient and/or
caregiver requests for selective COX-2 NSAIDs
decreased in frequency (p < .001) following the drug
withdrawals. Similarly, physician prescribing habits
changed after the drug withdrawals. Of the pediatric
rheumatologists who responded, 44% reported an
increased number of prescriptions of traditional
NSAIDs, 53% reported no change in prescribing habits,
and 3% reported giving fewer traditional NSAID pre-
scriptions. For selective COX-2 NSAIDs, however, less
than 1% of pediatric rheumatologists increased prescrib-
ing, 57% gave fewer prescriptions, and 26% reported
that they no longer prescribed these medications.
Barriers to prescribing selective COX-2 NSAIDs for
pediatric patients were examined; at the time of this sur-
vey, no drug in this class had a pediatric indication.
Cost, lack of testing in children, lack of insurance cover-
age and no available liquid formulation were reported as
barriers “occasionally” or “frequently” by at least 25% of
respondents who prescribed these drugs (Figure 3).
Prescribing Habits by Specialty
Physicians were asked how often they prescribed each of
the available NSAIDs (not just those with pediatric indi-
cations). Non-rheumatologists “frequently” (more than
once per week) prescribed ibuprofen, naproxen, and
ketorolac, and “rarely” (less than once per year) pre-
scribed any other drug in this class. Eighty percent of
pediatric surgeons and 52% of orthopedic surgeons
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month) or “frequently”. Pediatric rheumatologists pre-
scribed a wider range of drugs, but only ibuprofen,
diclofenac, indomethacin, naproxen, celecoxib and rofe-
coxib were prescribed by at least 40% of the sample.
Discussion
This study is the first to examine pediatric physicians’
perceptions of the safety and tolerability of NSAIDs as
prescribed for their pediatric patients. Overall, physi-
cians who responded to this survey regard NSAIDs -
both traditional and selective COX-2 - as safe for use in
the pediatric population. NSAIDs were frequently pre-
scribed for musculoskeletal and soft tissue pain, fol-
lowed by fever, headaches, and juvenile arthritis. The
most commonly observed side effects were abdominal
pain, epistaxis, bruising, headache and fatigue. Signifi-
cantly fewer prescriptions of selective COX-2 NSAIDs
were written since the voluntary withdrawal of two
drugs in this class, although observed side effects were
reported significantly less frequently among children
who received these medicines. Although the survey data
are subjective, little published safety data of selective
COX-2 NSAID use in children exists. Facing a lack of
available data, the prescribing of and taking of all
NSAIDs has recently come under close scrutiny.
Survey Bias
This survey was distributed to a large number of physi-
cians, with a 28% completion rate; lower than the aver-
age mail survey response rate[28], but consistent with
literature that suggests a lower response rate for web-
Table 1 “Occasional” and “Frequent” NSAID Side Effects Reported by Rheumatologists
Side Effect number reported, (% of total) Traditional (n = 99) COX-2 (n = 95) p-value
Abdominal Pain 80 (81) 22 (23) < .001
Gastric/duodenal ulcer 6 (6) 2 (2) 0.28
Hematuria 4 (4) 1 (1) 0.37
Hypertension 3 (3) 3 (3) 1.0
Thrombocytopenia 1 (1) 0 (0) 1.0
Epistaxis 13 (13) 2 (2) .006
Easy Bruising 63 (64) 8 (8) < .001
Headache 21 (21) 1 (1) < .001
Fatigue 12 (12) 1 (1) .003
“occasional” = reported more than once per month, “frequent” = reported more than once per week, COX = cyclooxygenase. Only pediatric rheumatologists who
prescribed these drugs were included, therefore, the sample sizes of the comparison groups were different. Statistical comparisons were made by Fisher’s exact
test.
Figure 1 COX-2 versus Traditional NSAIDs: Physician Perceived Differences are Minimal Except for Tolerability. Respondents compared
selective COX-2 NSAIDs to traditional nonselective NSAIDs for their safety, pain relief, anti-inflammatory effects and tolerability; available choices
were “less effective”, “equally effective”, “more effective”,o r“cannot give an opinion” (not shown).
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sible bias, and thus the validity of the study, it is likely
that the data are skewed toward over-reporting of
NSAID side effects. Presumably, physicians who fol-
lowed the reporting of NSAID concerns developed opi-
nions (either positive or negative), and were more likely
to respond to the introductory email explaining the
objectives. Respondents were also more likely interested
in how NSAIDs are prescribed and by whom they are
taken. There were many reasons that physicians chose
not to respond, specific comments included “the
overabundance of surveys received”, while a lack of time
and energy, lack of interest or personal applicability to
the subject matter, and a general reluctance to partici-
pate in another’s research were reported by nonpartici-
pants. These reasons are consistent with the recent
medical survey literature[32,33]. Many of the recom-
mended strategies to improve response rates were
employed, including sending reminders, using email as a
communication tool, offering minimal incentives (lottery
tickets), and personalizing the introductory emails
[30,31,34].
This study was skewed to include a large percentage
of pediatric rheumatologists, as the investigators were
particularly interested in physician groups with extensive
experience prescribing NSAIDs. Survey responses were
based on subjective pooling of data - i.e. physicians were
asked to estimate how often they observed specific side
effects, or how often they prescribed specific drugs.
Respondents were not asked to recall specific patients
or to provide numerical frequencies of prescribing, thus,
the data were possibly biased toward either over- or
underreporting, depending on the actual frequency of
the side effect observed in practice - common side
effects may have been underreported and rare side
effects overreported.
Prescribing Habits and Barriers
Despite the study limitations, the data confirms that
pediatricians and pediatric subspecialists continue to
prescribe NSAIDs (98% of respondents have prescribed
an NSAID for a pediatric patient), but that known side
Figure 2 Patient/Caregiver requests for selective COX-2 NSAIDs
have decreased since the voluntary withdrawal of rofecoxib
and valdecoxib*. *These distributions are significantly different (p <
0.001) by chi-squared analysis with Stuart-Maxwell test of
homogeneity. Rarely = more than once per year, occasionally =
more than once per month, frequently = more than once per week.
Figure 3 Barriers to Prescribing Selective COX-2 NSAIDs. *Percentage of all responses that were either “occasionally” (more than once per
month) or “frequently” (more than once per week).
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NSAIDs have been prescribed by just over half of all
respondents, suggesting either a decreased perception of
need, or recent apprehension of these medications. Fac-
tors for not prescribing specific NSAIDs included a per-
ceived lack of efficacy, perceived danger by either
physicians or patients, lack of testing in pediatric popu-
lations, greater expense, lack of appropriate (liquid) for-
mulation, and lack of an FDA-approved pediatric
indication. Many physicians also expressed unfamiliarity
with the specific COX-2 NSAIDs.
The survey asked physicians to consider only their
NSAID prescribing habits, thus, it did not capture data
about general prescribing habits for disease, nor did it
attempt to quantify “co-prescribing”, for example, the
number of patients who received other drugs such as
methotrexate or a biologic response modifier, in addi-
tion to an NSAID, for the treatment of juvenile arthritis.
Safety of NSAIDs in Children
Side effects of NSAIDs are common, but severe side
effects are rare in children. A review of the safety litera-
ture of NSAID use in pediatrics revealed controlled stu-
dies of ibuprofen, ketorolac, naproxen, meloxicam,
rofecoxib and celecoxib. The largest randomized trial of
ibuprofen (versus acetaminophen) included more than
84,000 children with fever. The observed risk of gastro-
intestinal bleeding in the ibuprofen group was 7.2 per
100,000, not significantly different from the comparison
group[35]. An older study demonstrated a dose-response
relationship with ibuprofen and adverse gastrointestinal
reactions[36]. A recent Cochrane Review concluded that
ibuprofen should not be used prophylactically for PDA
closure because of potential side effects including
decreased urine output, increased creatinine, and pul-
monary hypertension[37].
Studies of ketorolac to determine its safety for neo-
nates after cardiac surgery have demonstrated no signifi-
cant increase in wound or gastrointestinal bleeding, or
changes in renal function[38-40]. In older children, no
significant increased incidence of bleeding was observed
in three separate studies[41-43]; however, one observa-
tional study demonstrated two potentially associated
bleeding events[44]. The current study confirms that
ketorolac was prescribed frequently by surgeons and
non-surgical specialists alike, without reported bleeding
side effects.
A randomized, double-blind trial of meloxicam versus
naproxen for juvenile arthritis reported gastrointestinal
symptoms in up to 38% of subjects, and other adverse
events including headache and rash in fewer than 15%.
No ulcerations, perforations or major bleeds were
reported although “bleeding disorders” (rectal, epistaxis,
hematuria, hematoma, purpura) were reported in 6.2%
[45]. Another study reported adverse events (abdominal
pain, diarrhea, nausea and increased hepatic enzymes or
blood urea nitrogen) in 11% of patients believed to be
related to the drug[46]. In this survey, meloxicam was
prescribed predominantly by pediatric rheumatologists,
probably due to the lack of studies for any other
indication.
Two randomized double-blind, placebo controlled
trials of rofecoxib in children undergoing adenotonsil-
lectomy noted no increased bleeding due to rofecoxib
[16,17]. A randomized double-blind, double-dummy
study of rofecoxib versus naproxen for juvenile arthritis
reported abdominal pain in up to 39% of subjects in
each group (no significant difference). Headache, rash,
pharyngitis and upper respiratory infections were
observed in fewer than 15%, and two cases of edema
were deemed possibly or probably related to the drug
[19].
The pediatric literature of non-controlled studies of
NSAID safety includes reports of reversible renal failure
and significant gastropathy[47-51]. In this survey,
adverse renal events were rarely reported, probably an
underreporting bias since questions addressed only
hematuria and hypertension, and did not ask about epi-
sodes of renal failure. The largest study of gastropathy
in children taking NSAIDs retrospectively reviewed 702
patients with juvenile arthritis; five children with 10 gas-
tropathy events were documented by barium swallow or
endoscopy and thought to be attributable to NSAIDs[9].
Gastropathy may occur more frequently, as another
s t u d yo f1 4c h i l d r e nw i t hj uvenile arthritis taking
NSAIDs for at least one year demonstrated endoscopic
lesions in 43%, abdominal pain in 27% and H. pylori in
57%[52]. Recently, four children given ibuprofen for
fever developed isolated gastric antral ulcers following
the first or second dose[10]. The current survey was not
designed to ascertain the incidence of gastropathy; how-
ever, physicians reported abdominal pain as a frequent
side effect, and ulceration as a rare side effect.
Tolerability of NSAIDs in Children
This survey demonstrated a lower frequency of several
observed side effects when selective COX-2 NSAIDs
were prescribed compared to traditional NSAIDs. Eighty
percent of physicians reported observing “occasional” to
“frequent” abdominal pain for traditional NSAIDs, com-
pared to 23% for selective COX-2 NSAIDs (p < .001).
This finding may be biased, as patients with abdominal
pain were more likely to receive selective COX-2
NSAIDs with the expectation that their abdominal pain
would resolve. Other significant differences were
observed in the frequency of headaches, epistaxis, fati-
gue and easy bruising. As the duration and breadth of
experience with selective COX-2 NSAIDs is less (fewer
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be unusual unless they commonly occur. This is true of
the adult literature, where cardiovascular side effects of
selective COX-2 NSAIDs were only noted after thou-
sands of patients were studied[7]. Collectively, pediatric
rheumatologists have thousands of patient years of
experience prescribing traditional NSAIDs, and perhaps
only hundreds with the selective COX-2 NSAIDs,
thereby accounting for fewer observed, or perceived side
effects.
Cardiovascular Side Effects of NSAIDs
In this sample of 338 physicians, eleven reported one or
more adverse cardiovascular events in patients taking
NSAIDs. All of the events were attributed to an underly-
ing medical diagnosis (complex congenital heart disease,
systemic lupus erythematosus, sickle cell anemia, or
antiphospholipid syndrome), and none of these events
were attributed to NSAID use. Thus, both traditional
and selective COX-2 NSAIDs were perceived as safe for
pediatric patients.
Conclusions
At present, there are nine traditional NSAIDs (aspirin,
etodolac, ibuprofen, indomethacin, ketorolac, meloxi-
cam, naproxen, oxaprozin, and tolmetin) and one selec-
tive COX-2 NSAID (celecoxib) with FDA-approved
pediatric indications. Thus study suggests that pediatri-
cians are comfortable prescribing the traditional
NSAIDs, but few practitioners aside from rheumatolo-
gists prescribe selective COX-2 NSAIDs. Recent publica-
tions and media attention have altered attitudes towards
NSAID prescribing. The published safety data of these
drugs in pediatrics are limited, although few serious
adverse events have been reported. Pediatric pharmaco-
kinetics and risk factors differ from adults, thus phase
IV, open-label post-marketing studies of these drugs as
prescribed for children must be initiated in order to
accurately assess the potential risks of this valuable class
of medications. Otherwise, physician and patient percep-
tions of these drugs will continue to bias clinical
practice.
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